Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence

Prostate Cancer and Prostatic Diseases

Volumn 13, Issue 4, 2010, Pages 311-315

  Hawksworth, D ^a   Ravindranath, L ^b   Chen, Y ^b   Furusato, B ^c   Sesterhenn, I A ^c   Mcleod, D G ^a,b   Srivastava, S ^b   Petrovics, G ^b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

Author keywords

C MYC oncogene; quantitative expression; recurrence

Indexed keywords

MYC PROTEIN; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER RECURRENCE; CONTROLLED STUDY; ERG GENE; GENE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; LASER CAPTURE MICRODISSECTION; MALE; ONCOGENE C MYC; PCA3 GENE; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATECTOMY; PROTEIN EXPRESSION; TUMOR CELL;

ADENOCARCINOMA; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; HUMANS; MALE; ONCOGENES; PROGNOSIS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC; RECURRENCE; RNA, MESSENGER; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 78649322562     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2010.31     Document Type: Article

References (24)

1. American Cancer Society: Cancer Facts & Figures 2009. http://www.cancer.org.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. Cancer J Clin 2009; 59: 225-249.
3. Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part II: individual countries. BJU Int 2002; 90: 174-184.
4. Bubendorf L, Kononen J, Koivisto P, Schraml P, Moch H, Gasser TC et al. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res 1999; 59: 803-806.
5. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007; 7: 256-269.
6. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer 2008; 8: 491-511.
7. Gurel B, Iwata T, Koh CM, Yegnasubramanian S, Nelson WG, De Marzo AM. Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic agents? Adv Anat Pathol 2008; 15: 319-331.
8. Quinn DI, Henshall SM, Sutherland RL. Molecular markers of prostate cancer outcome. Eur J Cancer 2005; 41: 858-887.
9. Williams K, Fernandez S, Stien X, Ishii K, Love HD, Lau YF et al. Unopposed C-MYC expression in benign prostatic epithelium causes a cancer phenotype. Prostate 2005; 63: 369-384.
10. Vita M, Henriksson M. The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol 2006; 16: 318-330.
11. Knoepfler PS. Myc goes global: new tricks for an old oncogene. Cancer Res 2007; 67: 5061-5063.
12. Gardner LB, Lee LA, Dang CV. C-myc protooncogene. In: Bertino JR (ed). Encyclopedia of Cancer. Elsevier Science: Amsterdam, 2002, pp 555-561.
13. Herold S, Herkert B, Eilers M. Facilitating replication ounder stress: an oncogenic function of MYC? Nat Rev Cancer 2009; 9: 441-444.
14. Fleming WH, Hamel A, MacDonald R, Ramsey E, Pettigrew NM, Johnston B et al. Expression of the C-MYC protooncogene in human prostatic carcinoma and benign prostatic hyperplasia. Cancer Res 1986; 46: 1535-1538.
15. Fox SB, Persad RA, Royds J, Kore RN, Silcocks PB, Collins CC. P53 and C-MYC expression in Stage A1 prostatic adenocarcino-ma: useful prognostic determinants? J Urol 1993; 150: 490-494.
16. Jenkins RB, Qian J, Lieber MM, Bostwick DG. Detection of C-MYC oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res 1997; 57: 524-531.
17. Qian J, Jenkins RB, Bostwick DG. Detection of chromosomal anomalies and C-MYC gene amplification in the cribriform pattern of prostatic intraepithelial neoplasia and carcinoma by fluorescence in situ hybridization. Mod Pathol 1997; 10: 1113-1119.
18. Sato H, Minei S, Hachiya T, Yoshida T, Takimoto Y. Fluorescence in situ hybridization analysis of C-MYC amplification in Stage T3N0M0 prostate cancer in Japanese patients. Int J Urol 2006; 13: 761-766.
19. Gurel B, Iwata T, Koh CM, Jenkins RB, Lan F, Van Dang C et al. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol 2008; 21: 1156-1167.
20. Petrovics G, Liu A, Shaheduzzaman S, Furusato B, Sun C, Chen Y et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 2005; 24: 3847-3852.
21. Mwamukonda K, Chen Y, Ravindranath L, Furusato B, Hu Y, Sterbis J et al. Quantitative expression of TMPRSS2 transcript in prostate tumor cells reflects TMPRSS2-ERG fusion status. Prostate Cancer Prostatic Dis 2010; 13: 47-51.
22. Latil A, Vidaud D, Valéri A, Fournier G, Vidaud M, Lidereau R et al. HTERT expression correlates with MYC over-expression in human prostate cancer. Int J Cancer 2000; 89: 172-176.
23. Xu LL, Sun C, Petrovics G, Makarem M, Furusato B, Zhang W et al. Quantitative expression profile of PSGR in prostate cancer. Prostate Cancer Prostatic Dis 2006; 9: 56-61.
24. Sun C, Dobi A, Mohamed A, Li H, Thangapazham RL, Furusato B et al. TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene 2008; 27: 5348-5353.